4 results
To confirm the safety of the Articulinx ICC by evaluating device- and procedure relates adverse events.
Objectives of part A:- evaluate the safety, tolerability and pharmacokinetics of 2, 3 or 4 mg AZ-009 after 5 days of dosing in people with Parkinson's disease- evaluate the safety, tolerability and pharmacokinetics of 2, 3 or 4 mg AZ-009 after…
To examine the safety, tolerability, and pharmacokinetic profile of single ascending doses of AZ-009 compared to placebo (part B and C) or to Apo-Go (part A) in healthy volunteers being pretreated with domperidone and in patients with Parkinson…
The primary objective of this study is to compare effectivity of suboxone and methadone on reducing opioid misuse.Secondary objectives include comparing the effects of these two medications on pain, well-being and medication use.